Construction of Predictive Models for Cancer-specific Survival of Patients with Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guerin: Results from a Multicenter Retrospective Study

被引:6
|
作者
Nishiyama, Naotaka [1 ]
Kitamura, Hiroshi [1 ]
Hotta, Hiroshi [2 ]
Takahashi, Atsushi [3 ]
Yanase, Masahiro [4 ]
Itoh, Naoki [5 ]
Tachiki, Hitoshi [6 ]
Miyao, Noriomi [7 ]
Matsukawa, Masanori [8 ]
Kunishima, Yasuharu [9 ]
Taguchi, Keisuke [10 ]
Masumori, Naoya [1 ]
机构
[1] Sapporo Med Univ, Dept Urol, Sch Med, Sapporo, Hokkaido 0608543, Japan
[2] Asahikawa Red Cross Hosp, Dept Urol, Asahikawa, Hokkaido, Japan
[3] Hakodate Goryoukaku Hosp, Dept Urol, Hakodate, Hokkaido, Japan
[4] Sunagawa City Med Ctr, Dept Urol, Sunagawa, Japan
[5] NTT East Japan Sapporo Hosp, Dept Urol, Sapporo, Hokkaido, Japan
[6] Steel Mem Muroran Hosp, Dept Urol, Muroran, Hokkaido, Japan
[7] Muroran City Gen Hosp, Dept Urol, Muroran, Hokkaido, Japan
[8] Takikawa Municipal Hosp, Dept Urol, Takikawa, Hokkaido, Japan
[9] Hokkaido Social Work Assoc Obihiro Hosp, Dept Urol, Obihiro, Hokkaido, Japan
[10] Oji Gen Hosp, Dept Urol, Tomakomai, Japan
关键词
non-muscle-invasive bladder cancer; bacillus Calmette-Guerin; BCG failure classification; UROTHELIAL CARCINOMA; PROGNOSTIC-FACTORS; RISK; MANAGEMENT; FAILURE; TUMORS; PROGRESSION; RECURRENCE; THERAPY; DISEASE;
D O I
10.1093/jjco/hyu119
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aims of this study were to clarify the prognostic factors and to validate the bacillus Calmette-Guerin failure classification advocated by Nieder et al. in patients with non-muscle-invasive bladder cancer who had intravesical recurrence after bacillus Calmette-Guerin therapy. Methods: Data from 402 patients who received intravesical bacillus Calmette-Guerin therapy between January 1990 and November 2011 were collected from 10 institutes. Among these patients, 187 with bacillus Calmette-Guerin failure were analyzed for this study. Results: Twenty-nine patients (15.5%) were diagnosed with progression at the first recurrence after bacillus Calmette-Guerin therapy. Eighteen (62.1%) of them died of bladder cancer. A total of 158 patients were diagnosed with non-muscle-invasive bladder cancer at the first recurrence after bacillus Calmette-Guerin therapy. Of them, 23 (14.6%) underwent radical cystectomy. No patients who underwent radical cystectomy died of bladder cancer during the follow-up. On multivariate analysis of the 135 patients with bladder preservation, the independent prognostic factors for cancer-specific survival were age (>= 70 [P = 0.002]), tumor size (>= 3 cm [P = 0.015]) and the Nieder classification (bacillus Calmette-Guerin refractory [P < 0.001]). In a subgroup analysis, the estimated 5-year cancer-specific survival rates in the groups with no positive, one positive and two to three positive factors were 100, 93.4 and 56.8%, respectively (P < 0.001). Conclusions: Patients with stage progression at the first recurrence after bacillus Calmette-Guerin therapy had poor prognoses. Three prognostic factors for predicting survival were identified and used to categorize patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin into three risk groups based on the number of prognostic factors in each one.
引用
收藏
页码:1101 / 1108
页数:8
相关论文
共 50 条
  • [31] The Efficiency of the EORTC Scoring System for the Prediction of Recurrence and Progression of Non-muscle-invasive Bladder Cancer Treated by Bacillus Calmette-Guerin Immunotherapy
    Ajili, Faouzia
    Darouiche, Amine
    Chebil, Mouhamed
    Boubaker, Samir
    ULTRASTRUCTURAL PATHOLOGY, 2013, 37 (04) : 249 - 253
  • [32] Replacement Instead of Discontinuation of Bacillus Calmette-Guerin Instillation in Non-Muscle-Invasive Bladder Cancer
    Lin, Po-Ting
    Hung, Wei-Kang
    Chang, Ying-Hsu
    Hsieh, Ming-Li
    Liu, Chung-Yi
    Huang, Liang-Kang
    Chu, Yuan-Cheng
    Kan, Hung-Cheng
    Lin, Po-Hung
    Yu, Kai-Jie
    Chuang, Cheng-Keng
    Wu, Chun-Te
    Pang, See-Tong
    Shao, I-Hung
    CANCERS, 2023, 15 (04)
  • [33] Analysis of sex-based differences to Bacillus Calmette-Guerin for non-muscle invasive bladder cancer
    Fadel, Jonathan
    Simonyan, David
    Fradet, Vincent
    Lodde, Michele
    Lacombe, Louis
    Fradet, Yves
    Toren, Paul
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2022, 40 (12) : 539.e1 - 539.e8
  • [34] Gemcitabine Versus Bacille Calmette-Guerin After Initial Bacille Calmette-Guerin Failure in Non-Muscle-Invasive Bladder Cancer A Multicenter Prospective Randomized Trial
    Di Lorenzo, Giuseppe
    Perdona, Sisto
    Damiano, Rocco
    Faiella, Adriana
    Cantiello, Francesco
    Pignata, Sandro
    Ascierto, Paolo
    Simeone, Ester
    De Sio, Marco
    Autorino, Riccardo
    CANCER, 2010, 116 (08) : 1893 - 1900
  • [35] Optimal schedule of bacillus calmette-guerin for non-muscle-invasive bladder cancer: a meta-analysis of comparative studies
    Zhu, Shimiao
    Tang, Yang
    Li, Kai
    Shang, Zhiqun
    Jiang, Ning
    Nian, Xuewu
    Sun, Libin
    Niu, Yuanjie
    BMC CANCER, 2013, 13
  • [36] Bacillus Calmette-Guerin may have clinical benefit for glandular or squamous differentiation in non-muscle invasive bladder cancer patients: retrospective multicenter study
    Yorozuya, Wakako
    Nishiyama, Naotaka
    Shindo, Tetsuya
    Kyoda, Yuki
    Itoh, Naoki
    Sugita, Shintaro
    Hasegawa, Tadashi
    Masumori, Naoya
    JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (07) : 661 - 666
  • [37] Effect of Bacille Calmette-Guerin for Non-Muscle-Invasive Bladder Cancer After Prostate Radiotherapy
    Durant, Adri M.
    Lee, Yeonsoo S.
    Mi, Lanyu
    Faraj, Kassem
    Lyon, Timothy D.
    Singh, Parminder
    Tyson, Mark D., II
    BLADDER CANCER, 2024, 10 (01) : 35 - 45
  • [38] Comparative study between mitomycin C versus Bacillus Calmette-Guerin (BCG) in high-risk non-muscle-invasive bladder cancer
    Zaza, Mohamed Mahmoud Abdelfatah
    Salem, Tarek Abd El-Mageed
    El-Sadat, Ahmed Mohamed
    Ali, Mohammed Hassan
    UROLOGIA JOURNAL, 2024, 91 (01) : 61 - 68
  • [39] Cancer-Specific Survival of Patients with Non-Muscle-Invasive Bladder Cancer: A Population-Based Analysis
    Slusarczyk, Aleksander
    Zapala, Piotr
    Zapala, Lukasz
    Borkowski, Tomasz
    Radziszewski, Piotr
    ANNALS OF SURGICAL ONCOLOGY, 2023, 30 (12) : 7892 - 7902
  • [40] Bacillus Calmette-Guerin unresponsiveness in non-muscle-invasive bladder cancer patients: what the urologists should know
    Moschini, Marco
    Zamboni, Stefania
    Mattei, Agostino
    Amparore, Daniele
    Fiori, Cristian
    De Dominicis, Carlo
    Esperto, Francesco
    MINERVA UROLOGICA E NEFROLOGICA, 2019, 71 (01) : 17 - 30